ACTH (Adrenocorticotropic Hormone): The Master Stress Peptide Driving HPA Axis, Melanocortin Signaling, and Extraadrenal Research (2026)

# ACTH (Adrenocorticotropic Hormone): The Master Stress Peptide Driving HPA Axis, Melanocortin Signaling, and Extraadrenal Research (2026)

Adrenocorticotropic hormone (ACTH), also known as corticotropin, is a 39-amino acid peptide hormone encoded within the pro-opiomelanocortin (POMC) precursor. It occupies a central node in the hypothalamic–pituitary–adrenal (HPA) axis, governing glucocorticoid synthesis, adrenal growth, and — through its family of melanocortin receptors — a wide spectrum of immune-modulatory, neuroprotective, and metabolic effects that extend far beyond the adrenal cortex.

For researchers in endocrinology, neuroscience, immunology, and peptide biology, ACTH represents a convergence point: a single peptide whose fragments gave rise to clinical neuroprotectants (such as Semax, derived from ACTH 4-10), whose C-terminal region links to the beta-endorphin and CLIP sequences of POMC, and whose receptor pharmacology underpins an entire family of melanocortin ligands including alpha-MSH (α-MSH) derivatives.

For research use only (RUO). All content on this page relates to laboratory and preclinical investigation. ACTH and its analogs are not approved for self-administration and must not be construed as medical advice.

---

Peptide Identity and POMC Origin

POMC is a ~241-amino acid precursor that is differentially cleaved by prohormone convertases (PC1/PC3 in the pituitary, PC2 in the hypothalamus and skin). In the anterior pituitary, PC1 releases ACTH (1–39) and beta-lipotropin (β-LPH). In the hypothalamus and skin, further processing by PC2 produces alpha-MSH from ACTH 1–13 (with C-terminal amidation) and the corticotropin-like intermediate lobe peptide (CLIP, ACTH 18–39). The first 13 residues of ACTH are identical to α-MSH, while the N-terminal 24 residues (ACTH 1–24, tetracosactide) retain full biological activity at the MC2R.

---

HPA Axis: The Core Regulatory Circuit

The hypothalamic–pituitary–adrenal (HPA) axis represents one of the body's principal stress-response systems. Its regulation proceeds through a hierarchical feedback chain:

Step 1 — Corticotropin-Releasing Hormone (CRH)

Hypothalamic paraventricular neurons release CRH (and the co-secretagogue arginine vasopressin, AVP) into the hypophyseal portal circulation in response to physical, psychological, or immune stressors. CRH binds to CRH receptor-1 (CRHR1) on anterior pituitary corticotrophs.

Step 2 — ACTH Synthesis and Release

CRHR1 activation triggers cAMP/PKA signaling, stimulating ACTH synthesis (via POMC transcription) and rapid secretion. ACTH is released in ultradian pulses superimposed on a circadian rhythm, with peak secretion in the early morning hours and a nadir late at night. Stress superimposes additional surges onto this pulsatile baseline.

Step 3 — Adrenal Cortisol Synthesis

ACTH travels through systemic circulation to the adrenal cortex, where it binds with high affinity to MC2R. Within minutes, cAMP-PKA signaling mobilizes cholesterol and upregulates steroidogenic acute regulatory protein (StAR), transporting cholesterol to the inner mitochondrial membrane — the rate-limiting step of steroidogenesis. The acute result is cortisol secretion from zona fasciculata cells; chronic ACTH stimulation also promotes adrenal hypertrophy.

Step 4 — Negative Feedback

Rising cortisol exerts negative feedback at both the hypothalamus (suppressing CRH and AVP expression) and the anterior pituitary (reducing corticotroph sensitivity to CRH). This glucocorticoid-sensitive feedback loop limits HPA axis activation and prevents prolonged cortisol excess. Low circulating glucocorticoids (as in adrenal insufficiency) remove this brake, causing chronically elevated ACTH — the diagnostic signature of primary adrenal insufficiency.

> Research Note: Researchers model HPA axis dysregulation using a variety of ACTH stimulation protocols (e.g., cosyntropin/tetracosactide challenge tests in animal models) and CRH-antagonist paradigms. Dysregulation of HPA axis feedback is a consistent finding in preclinical models of major depression, PTSD, and metabolic syndrome.

---

ACTH Receptor Biology: MC2R and Beyond

The MC2R — A Uniquely Selective Receptor

Of the five melanocortin receptors (MC1R–MC5R), MC2R is the most selective: it binds only ACTH and requires the full ACTH 1–24 sequence for activation. This selectivity is conferred by a unique extracellular domain architecture and the critical requirement for the melanocortin accessory protein 1 (MRAP1), a small single-pass transmembrane protein that is essential for MC2R trafficking to the plasma membrane and for high-affinity ACTH binding.

The structural basis of MRAP1-assisted ACTH–MC2R signaling was recently clarified by cryo-EM, revealing how MRAP1 stabilizes the receptor in a conformation that positions the MC2R N-terminus to capture the ACTH N-terminal HFRW pharmacophore (Cai et al., 2022, Cell Research).

MC2R expression sites:

• •Adrenal cortex (zona fasciculata and zona reticularis) — primary target
• •Adipocytes (moderate expression)
• •Osteoblasts and bone marrow stromal cells
• •Immune cells (variable)
• •Skin and hair follicle cells (low)

Extraadrenal Melanocortin Signaling

ACTH shares the first 13 amino acids with α-MSH and the HFRW core motif (residues 6–9) with all melanocortin peptides. This means that at supra-physiological concentrations, ACTH can activate MC1R, MC3R, MC4R, and MC5R — receptors distributed across the brain, immune system, and peripheral tissues.

This receptor promiscuity underpins many of ACTH's extraadrenal effects observed in research models — effects that persist in adrenalectomized animals and therefore cannot be mediated by cortisol.

---

Key Research Applications

1. Adrenal Physiology and Insufficiency Models

ACTH stimulation and suppression paradigms are foundational in adrenal research. The cosyntropin (tetracosactide / ACTH 1–24) stimulation protocol is widely used in preclinical models to probe adrenocortical reserve. Research with ACTH receptor knockout mice has defined the essential role of MC2R in zona fasciculata differentiation and glucocorticoid synthesis. Studies in MRAP1-deficient models have clarified the molecular basis of familial glucocorticoid deficiency type 1 (FGD1), a rare inherited MC2R signaling disorder.

Key reference: Physiology, Adrenocorticotropic Hormone (ACTH) — StatPearls/NCBI Bookshelf

2. Infantile Spasms — Neurological Research

ACTH (as repository corticotropin injection or synthetic ACTH/tetracosactide) has been studied for decades in infantile spasm research, and understanding its mechanism in this seizure disorder has generated substantial mechanistic inquiry into melanocortin neuromodulation.

Preclinical work by Stafstrom and colleagues demonstrated that ACTH reduces spasm frequency in animal models of epileptic spasms independently of adrenal function, implicating direct CNS melanocortin receptor activation. Clinical research has consistently shown cessation rates of 42–87% in infant cohorts treated with ACTH-based therapy.

A 2021 comparative analysis found that hormonal therapy including ACTH achieved early remission rates superior to vigabatrin as first-line treatment for infantile spasms (Neurology, 2022). A systematic review published in Frontiers in Neurology (2022) confirmed the meta-analytic superiority of hormonal therapy and highlighted the importance of early initiation (Frontiers Neurology, 2022).

A 2022 PMC study examining ACTH treatment patterns in 156 patients found that intravenous synthetic ACTH produced particularly rapid spasm cessation, informing protocol optimization research (PMC 9037564, 2022).

The working hypothesis in the field is that ACTH suppresses infantile spasms via MC4R-mediated neuromodulation in the developing brain, specifically by modulating CRH-driven hyperexcitability in limbic circuits.

3. Extraadrenal Anti-Inflammatory and Immune Research

ACTH's immunomodulatory potential is among its most actively researched extraadrenal properties. Multiple research lines converge:

Direct immune cell effects:

ACTH suppresses pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) in macrophage and monocyte models. It activates melanocortin receptors (primarily MC3R/MC4R) on immune cells, triggering anti-inflammatory intracellular cascades. This effect is independent of glucocorticoid secretion and has been documented in adrenalectomized animal models.

Cholinergic anti-inflammatory pathway:

Central MC4R stimulation by ACTH/melanocortins activates the vagal cholinergic anti-inflammatory pathway, leading to acetylcholine release at peripheral immune cell synapses and engagement of α7-nicotinic acetylcholine receptors (α7-nAChR). This circuit suppresses macrophage activation and inflammatory cytokine storm in sepsis models.

Multiple sclerosis research:

Repository corticotropin injection has been studied in relapsing-remitting MS models, with preclinical and clinical research suggesting that melanocortin-mediated immunomodulation — distinct from simple steroid replacement — may contribute to remission-induction. A comprehensive PMC review detailed the steroid-independent mechanisms relevant to clinical MS management (PMC 3573675, 2013).

For broader melanocortin immunology context, see the 2019 Frontiers in Endocrinology review on melanocortin regulation of inflammation (Frontiers Endocrinology, 2019).

4. Neuroprotection Research

ACTH and its fragments have been investigated in preclinical neuroprotection paradigms:

Ischemic stroke models:

Melanocortins including ACTH activate MC4R in the brain, triggering anti-apoptotic and anti-inflammatory cascades. In rodent middle cerebral artery occlusion (MCAO) models, ACTH and α-MSH administration reduced infarct volume and neurological deficit scores. The proposed mechanism involves MC4R-dependent upregulation of BDNF and activation of the cholinergic anti-inflammatory pathway.

Peripheral nerve regeneration:

ACTH/MSH-derived peptides have demonstrated promotion of axonal regeneration and neuromuscular junction recovery in sciatic nerve injury models. The N-terminal ACTH 4–10 fragment (absent adrenal activity) was instrumental in this research, eventually leading to development of neurotropic peptides including Semax (ACTH 4–7-Pro-Gly-Pro) — now studied independently as a neuroprotectant (see Semax research profile).

A 2026 PubMed study examined genes associated with ACTH-like peptides in rat brain ischemia models, mapping neuroprotective gene expression signatures in regions with varying ischemic vulnerability (PubMed 40650034, 2026).

5. CLIP Fragment and Corticosteroid-Independent Effects

CLIP (corticotropin-like intermediate lobe peptide, ACTH 18–39), the C-terminal cleavage product of ACTH in the intermediate lobe, has distinct research interest for its role in pancreatic beta-cell function and non-adrenal steroidogenesis research. While largely non-adrenotropic (unable to activate MC2R at physiological concentrations), CLIP demonstrates actions on pancreatic insulin secretion and has been investigated in metabolic research contexts.

6. Adrenal Growth and Trophic Research

Beyond acute steroidogenesis, ACTH is a potent trophic factor for the adrenal cortex. Chronic ACTH excess (as in Cushing's disease or ectopic ACTH secretion models) produces adrenal hyperplasia. Conversely, hypophysectomy or ACTH withdrawal rapidly induces adrenal atrophy. Research into adrenal zone-specific responses to ACTH has clarified the differential regulation of zona fasciculata (cortisol), zona reticularis (adrenal androgens DHEA/DHEA-S), and the relative ACTH-independence of zona glomerulosa (aldosterone).

A key paper on ACTH and related peptides on adrenal proliferation and growth: PubMed 27242663 (Comparative Effect of ACTH and Related Peptides on Proliferation and Growth of Rat Adrenal Gland).

---

ACTH Fragments and Research Analogs

The modularity of the ACTH sequence has made it a fertile source for fragment peptides with selective activities:

ACTH 1–24 (Tetracosactide / Cosyntropin)

The first 24 amino acids of ACTH retain full agonist potency at MC2R and are used in synthetic form (tetracosactide, cosyntropin) for adrenal stimulation testing in research and diagnostic contexts. Tetracosactide is more resistant to enzymatic degradation than full-length ACTH 1–39. Pharmacokinetic research has explored lipid-modified ACTH analogs with extended half-lives — one study found lipophilized ACTH variants exhibited higher biological activity and longer serum half-lives than native ACTH (PubMed 12950006).

ACTH 1–13 (α-MSH)

The first 13 residues of ACTH, with C-terminal amide modification, constitute α-MSH — the endogenous agonist at MC1R, MC3R, MC4R, and MC5R. α-MSH has no significant activity at MC2R. This sequence divergence explains why α-MSH potently modulates pigmentation, immune function, and energy homeostasis while exerting minimal adrenotrophic effect.

ACTH 4–10 (Core Neuropeptide)

This heptapeptide fragment (Met-Glu-His-Phe-Arg-Trp-Gly) contains the HFRW melanocortin pharmacophore. It lacks adrenotropic activity but retains neuromodulatory effects in CNS research models. It served as the template for development of Semax (ACTH 4-7-Pro-Gly-Pro), a stabilized fragment with neuroprotective and cognitive-enhancing properties in preclinical research.

ACTH 4–7 (MEHFR)

Subset of the above; the minimal sequence required for neurotrophic effects in some model systems.

ACTH 18–39 (CLIP)

The corticotropin-like intermediate lobe peptide; pancreatic and intermediate lobe research.

---

Pharmacokinetics of ACTH in Research Contexts

The short plasma half-life of ACTH in research models necessitates either continuous infusion protocols or the use of longer-acting analogs (repository corticotropin — a gel-based formulation in clinical contexts — or modified peptides in preclinical work).

---

Research Tools and Models

Genetic Models

• •MC2R knockout mice: Selectively lack adrenal ACTH signaling; used to isolate extraadrenal ACTH effects
• •MRAP1 knockout: Models familial glucocorticoid deficiency type 1 (FGD1)
• •POMC knockout mice: Lack all POMC-derived peptides including ACTH, β-endorphin, and α-MSH; exhibit obesity, adrenal insufficiency
• •Corticotroph-specific Cre models: Allow conditional manipulation of ACTH synthesis

Pharmacological Approaches

• •ACTH receptor antagonists: Astatine-211-labeled ACTH antagonists in adrenocortical carcinoma research
• •CRH antagonists: Upstream suppression of ACTH secretion in stress research
• •Metyrapone / adrenalectomy: Eliminate cortisol to unmask glucocorticoid-independent ACTH effects

---

ACTH in Disease Research Models

Cushing's Syndrome Research

Pathological ACTH excess (from pituitary corticotropinomas — Cushing's disease — or ectopic ACTH-secreting tumors) produces chronic glucocorticoid excess. Research models use ACTH-secreting tumor xenografts or corticotropin infusion to replicate the metabolic sequelae: central adiposity, glucose intolerance, hypertension, bone loss, and immunosuppression.

Primary Adrenal Insufficiency (Addison's Disease) Models

Autoimmune adrenal destruction or adrenalectomy in rodent models drives chronically elevated ACTH (removing negative feedback), allowing researchers to study compensatory melanocortin signaling and the consequences of isolated glucocorticoid deficiency.

Depression and PTSD Research

HPA axis hyperactivity — elevated basal ACTH and cortisol, blunted feedback — is reproducibly observed in preclinical models of chronic stress and corresponds to core features of major depression and PTSD. ACTH measurement in these models provides a readout of HPA axis tone.

Obesity and Metabolic Research

ACTH stimulates lipolysis in adipocytes via MC2R-cAMP-PKA signaling, but MC5R-mediated effects in exocrine and immune tissues and MC3R/MC4R-mediated central effects on energy homeostasis interweave with ACTH's peripheral actions. Adrenal-cortical interactions with adipose tissue are increasingly studied in the context of metabolic syndrome.

---

ACTH Measurement in Research

Assay Considerations

• •Pre-analytical handling critical: ACTH degrades rapidly at room temperature; samples must be collected in EDTA tubes on ice and centrifuged immediately
• •Immunoradiometric assay (IRMA): Traditional gold standard
• •Two-site ELISA: Preferred in modern research; high sensitivity (~1–2 pg/mL)
• •LC-MS/MS: Emerging for absolute quantification and fragment differentiation

Researchers studying circadian ACTH rhythms typically sample at multiple time points (0800h, 1600h, 2400h) to capture peak, midpoint, and nadir values. Stress-reactive ACTH research uses serial sampling with defined stressor paradigms (restraint stress, forced swim, etc.).

---

ACTH vs. Related Peptides: Comparative Overview

This comparative context situates ACTH within the broader peptide research landscape and illustrates why fragment-based drug design from ACTH has been so productive.

---

Sourcing ACTH and Analogs for Research

ACTH 1–39 and ACTH 1–24 (tetracosactide) are available from peptide synthesis companies and specialty research chemical suppliers. When evaluating sources, researchers should confirm:

• •HPLC purity ≥ 98% for biological research (sequence-verified peptides with ≥98% purity by RP-HPLC)
• •Mass spectrometry (MS) confirmation of molecular weight
• •Certificate of Analysis (CoA) with lot-specific data
• •Sterile filtration for in vitro cell culture applications
• •Endotoxin testing if intended for in vivo animal model work

For detailed guidance on evaluating peptide quality documentation, see the How to Read a Peptide Certificate of Analysis guide and Understanding Peptide Purity guide.

---

Summary

ACTH is far more than a simple adrenal stimulant. Its biology spans:

• •HPA axis regulation — the master stress-response peptide linking hypothalamic CRH input to adrenal glucocorticoid output with precision negative feedback
• •MC2R-mediated steroidogenesis — acute cholesterol mobilization and chronic adrenal trophic effects via cAMP-PKA-StAR signaling
• •Extraadrenal melanocortin signaling — immune modulation, neuroprotection, and anti-inflammatory effects mediated through MC1R, MC3R, and MC4R in a glucocorticoid-independent manner
• •Infantile spasm research — a key model system for understanding melanocortin neuromodulation during critical periods of brain development
• •Fragment pharmacology — a template for multiple research peptides including tetracosactide, α-MSH, KPV, CLIP, and Semax

For researchers working at the intersection of stress biology, immunology, or peptide neuroscience, ACTH is an indispensable reference peptide whose full pharmacological repertoire continues to be elaborated.

---

All information presented is for research and educational purposes only. ACTH and its analogs are research-use-only (RUO) compounds. They are not approved for human therapeutic use outside of specific regulated clinical applications and must not be self-administered. Always consult applicable institutional guidelines when working with peptide research compounds.